Voyager Therapeutics Enters Gene Therapy Collaboration with Neurocrine for Up to $1.96B in Milestones

Voyager Therapeutics, Inc.

Neurocrine pays Voyager $136M upfront (net of $39M stock purchase) for GBA1 and three CNS gene therapy programs.
Voyager eligible for up to $985M in development milestones for GBA1 and up to $175M per New Discovery Program.
Commercial milestones up to $950M per GBA1 product and $275M per New Discovery product; tiered royalties also apply.
Neurocrine purchases 4,395,588 shares of Voyager common stock at $8.88/share (~$39M) under a separate stock purchase agreement.
Voyager shifts Huntington's disease program to vectorized siRNA approach using proprietary TRACER capsids.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Voyager Therapeutics, Inc. entered into Collaboration and License Agreement with Neurocrine Biosciences, Inc. (effective 2023-01-08).

Action: entry
Agreement: collaboration
Counterparty: Neurocrine Biosciences, Inc.
Effective: 2023-01-08

Exact text from the filing

On January 8, 2023 (the “Agreement Date”), Voyager Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Neurocrine Biosciences, Inc. (“Neurocrine”) for the research, development, manufacture and commercialization of gene therapy products directed to the gene that encodes glucosylceramidase beta 1 (“GBA1”)

View on SEC.gov

Browse all material agreements →

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-002047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.